About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 965841, 7 pages
http://dx.doi.org/10.1155/2013/965841
Review Article

N-Terminal Plasmodium vivax Merozoite Surface Protein-1, a Potential Subunit for Malaria Vivax Vaccine

1Universidade Federal do Amazonas, Avenida General Rodrigo Octávio Jordão Ramos 3000, Campus Universitário, Coroado I, 69077-000 Manaus, AM, Brazil
2Instituto Leônidas e Maria Deane-Fiocruz, Rua Teresina 476, 69057-070 Manaus, AM, Brazil

Received 24 April 2013; Accepted 14 August 2013

Academic Editor: Wuelton Marcelo Monteiro

Copyright © 2013 Fernanda G. Versiani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The human malaria is widely distributed in the Middle East, Asia, the western Pacific, and Central and South America. Plasmodium vivax started to have the attention of many researchers since it is causing diseases to millions of people and several reports of severe malaria cases have been noticed in the last few years. The lack of in vitro cultures for P. vivax represents a major delay in developing a functional malaria vaccine. One of the major candidates to antimalarial vaccine is the merozoite surface protein-1 (MSP1), which is expressed abundantly on the merozoite surface and capable of activating the host protective immunity. Studies have shown that MSP-1 possesses highly immunogenic fragments, capable of generating immune response and protection in natural infection in endemic regions. This paper shows humoral immune response to different proteins of PvMSP1 and the statement of N-terminal to be added to the list of potential candidates for malaria vivax vaccine.